文章基本信息

标题：Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib
本地全文：下载
作者：Michael Davidson ; Sherry Xueyu Liu ; Philip Barter 等
期刊名称：JLR Papers In Press
印刷版ISSN：0022-2275
电子版ISSN：1539-7262
出版年度：2013
卷号：54
期号：2
页码：467-472
DOI：10.1194/jlr.M032615
语种：English
出版社：American Society for Biochemistry and Molecular Biology
摘要：Estimation of low-density lipoprotein cholesterol (LDL-C) using the Friedewald (FR) formula is often inaccurate when triglycerides are elevated or VLDL particle composition is altered. We hypothesized that LDL-C estimation by the FR formula and other measurement methods might also be inaccurate in individuals treated with a cholesteryl ester transfer protein (CETP) inhibitor. An assay comparison study was conducted using pre and posttreatment serum samples from 280 of the 811 patients treated with the CETP inhibitor anacetrapib in the DEFINE study (determining the ef ficacy and tolerability of CETP in hibition with anac e trapib). After 24 weeks of treatment with anacetrapib, mean LDL-C values by FR formula, Roche direct method (RDM) and Genzyme direct method (GDM) deviated from that measured by the β-quantification (BQ) reference method by –12.2 ± 7.5, –10.2 ± 6.6, –10.8 ± 8.8 mg/dl, respectively. After treatment with anacetrapib, the FR formula and detergent-based direct methods provided lower LDL-C values than those obtained by the BQ reference method. The bias by the FR formula appeared to be due to an overestimation of VLDL-C by the TG/5 component of the formula. Evaluation of the clinical significance of these findings awaits comprehensive lipid and cardiovascular outcome data from ongoing Phase III clinical studies of anacetrapib.
关键词：Friedewald formula ; β quantification ; VLDL cholesterol ; HDL cholesterol ; direct method ; low density lipoprotein cholesterol ; cholesteryl ester transfer protein